• Chen Qi Zhang, Ke Xin Zheng, Ling Qi Sun, and Hongbin Sun.
• Department of Special Medical, Chengdu BOE hospital, Chengdu, Sichuan Province, China.
• Medicine (Baltimore). 2021 Dec 23; 100 (51): e28161e28161.

BackgroundWith the aging population, the prevalence and incidence of dementia disease will continue to rise, and the associated economic burden is increasing as well. However, the available anti-dementia therapeutic arsenal is limited. Meanwhile, magnesium valproate (VPM) as an adjuvant therapy had a general positive effect on the cognitive function and psychiatric symptoms of patient with dementia (PwD). At present, there is lack of meta-analysis focusing on cognitive improvement and disease-modifying about VPM-assisted therapy in the present peer-reviewed literature. Thus, we aimed to likely analyze the efficacy and safety of VPM adjuvant therapy of PwD.MethodsWe will research MEDLINE via PubMed, Cochrane Library, EBSCO, Embase, China National Knowledge (CNKI) and Wan fang databases to gather relevant data on VPM assistant therapy on the PwD. Meta-analysis will be performed using Stata16.0 software.ResultsWe aim to evaluate the efficacy and safety of VPM in the adjuvant treatment of PwD.ConclusionVPM maybe plays an active role in the treatment of dementia patients and this research will provide reliable evidence for clinicians in therapy of PwD.Inplasy Registration NumberINPLASY2021110038 (DOI: 10.37766/inplasy2021.11.0038).Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

27 keywords...

hide…